BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 8910274)

  • 1. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape.
    Hahne M; Rimoldi D; Schröter M; Romero P; Schreier M; French LE; Schneider P; Bornand T; Fontana A; Lienard D; Cerottini J; Tschopp J
    Science; 1996 Nov; 274(5291):1363-6. PubMed ID: 8910274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
    Greil R; Egle A; Villunger A
    Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor cells fight back to beat immune system.
    Williams N
    Science; 1996 Nov; 274(5291):1302. PubMed ID: 8966600
    [No Abstract]   [Full Text] [Related]  

  • 4. Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing.
    Rivoltini L; Radrizzani M; Accornero P; Squarcina P; Chiodoni C; Mazzocchi A; Castelli C; Tarsini P; Viggiano V; Belli F; Colombo MP; Parmiani G
    J Immunol; 1998 Aug; 161(3):1220-30. PubMed ID: 9686582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures.
    Frost PJ; Butterfield LH; Dissette VB; Economou JS; Bonavida B
    J Immunol; 2001 Mar; 166(5):3564-73. PubMed ID: 11207317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent downregulation of Fas (CD95) expression and function in melanoma.
    Bullani RR; Wehrli P; Viard-Leveugle I; Rimoldi D; Cerottini JC; Saurat JH; Tschopp J; French LE
    Melanoma Res; 2002 Jun; 12(3):263-70. PubMed ID: 12140383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition.
    Zaks TZ; Chappell DB; Rosenberg SA; Restifo NP
    J Immunol; 1999 Mar; 162(6):3273-9. PubMed ID: 10092779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma.
    Uzzo RG; Rayman P; Kolenko V; Clark PE; Bloom T; Ward AM; Molto L; Tannenbaum C; Worford LJ; Bukowski R; Tubbs R; Hsi ED; Bander NH; Novick AC; Finke JH
    Clin Cancer Res; 1999 May; 5(5):1219-29. PubMed ID: 10353760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of the Fas-triggered intracellular signaling pathway in human melanomas is circumvented by cytotoxic lymphocytes.
    Ferrarini M; Imro MA; Sciorati C; Heltai S; Protti MP; Pellicciari C; Rovere P; Manfredi AA; Rugarli C
    Int J Cancer; 1999 May; 81(4):573-9. PubMed ID: 10225447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.
    Hashimoto W; Osaki T; Okamura H; Robbins PD; Kurimoto M; Nagata S; Lotze MT; Tahara H
    J Immunol; 1999 Jul; 163(2):583-9. PubMed ID: 10395644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fas ligand-induced apoptosis as a mechanism of immune privilege.
    Griffith TS; Brunner T; Fletcher SM; Green DR; Ferguson TA
    Science; 1995 Nov; 270(5239):1189-92. PubMed ID: 7502042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Membrane Fas ligand activates innate immunity and terminates ocular immune privilege.
    Gregory MS; Repp AC; Holhbaum AM; Saff RR; Marshak-Rothstein A; Ksander BR
    J Immunol; 2002 Sep; 169(5):2727-35. PubMed ID: 12193747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand.
    von Bernstorff W; Spanjaard RA; Chan AK; Lockhart DC; Sadanaga N; Wood I; Peiper M; Goedegebuure PS; Eberlein TJ
    Surgery; 1999 Jan; 125(1):73-84. PubMed ID: 9889801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: the Fas counterattack.
    O'Connell J; Bennett MW; O'Sullivan GC; Collins JK; Shanahan F
    Dis Esophagus; 1999; 12(2):83-9. PubMed ID: 10466039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance.
    Villunger A; Egle A; Marschitz I; Kos M; Böck G; Ludwig H; Geley S; Kofler R; Greil R
    Blood; 1997 Jul; 90(1):12-20. PubMed ID: 9207432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fas and Fas ligand expression in tumor cells and in vascular smooth-muscle cells of colonic and renal carcinomas.
    Peduto Eberl L; Guillou L; Saraga E; Schröter M; French LE; Tschopp J; Juillerat-Jeanneret L
    Int J Cancer; 1999 May; 81(5):772-8. PubMed ID: 10328232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fas-mediated apoptosis of melanoma cells and infiltrating lymphocytes in human malignant melanomas.
    Shukuwa T; Katayama I; Koji T
    Mod Pathol; 2002 Apr; 15(4):387-96. PubMed ID: 11950912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Death of solid tumor cells induced by Fas ligand expressing primary myoblasts.
    Hofmann A; Blau HM
    Somat Cell Mol Genet; 1997 Jul; 23(4):249-57. PubMed ID: 9542527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo.
    Rensing-Ehl A; Frei K; Flury R; Matiba B; Mariani SM; Weller M; Aebischer P; Krammer PH; Fontana A
    Eur J Immunol; 1995 Aug; 25(8):2253-8. PubMed ID: 7545115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transgenic expression of CD95 ligand on thyroid follicular cells confers immune privilege upon thyroid allografts.
    Tourneur L; Malassagne B; Batteux F; Fabre M; Mistou S; Lallemand E; Lores P; Chiocchia G
    J Immunol; 2001 Aug; 167(3):1338-46. PubMed ID: 11466351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.